Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Cardiology · J Am Heart Assoc · 2026-10-16
Secondary analysisn = 1,222
Gonzalez-Manzanares et al. Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI TrialCardiology · JAMA · 2026-09-01
RCTn = 784
Oosterom-Eijmael et al. Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical TrialTransplantation · J Heart Lung Transplant · 2026-08-31
RCTn = 52
Ersbøll et al. Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trialDiabetes and endocrinology · Diabetologia · 2026-07-17
RCTn = 24
Vergès et al. Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL1/VLDL2 catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic studyNephrology · Nephrol Dial Transplant · 2026-06-30
RCTn = 30
Vajgel et al. Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trialTransplantation · Transplantation · 2026-05-08
RCTn = 208
David-Neto et al. The Effect of Adding Dapagliflozin on Chronic Renal Allograft Dysfunction: A Randomized, Prospective, Double-blind, Placebo-controlled TrialNephrology · Clin J Am Soc Nephrol · 2025-12-12
RCTn = 52
Sridhar et al. Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled TrialCardiology · Hypertension · 2025-12-05
RCTn = 51
Sridhar et al. Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial